Objective. To evaluate to what extent rheumatologists consider economic aspects and patients' preferences when choosing drug treatments in patients with active RA.
Introduction
During the past decades, the management paradigm of patients with RA has changed. The introduction of the concept of early aggressive treatment and later of biologic DMARDs (bDMARDs) fundamentally improved disease outcomes for the majority of patients [1, 2] . However, these innovations and especially the bDMARDs increased treatment costs dramatically [3] . The impact of biologics on national health care budgets has been huge and most societies regulate access by restricting their use [4, 5] . While rheumatologists argue that treatment innovations should be available to all patients, they also realize that health care resources are not infinite. Over the past decade, cost-effectiveness considerations became part of international treatment guidelines [6] . In clinical practice, however, trade-offs based on cost-effectiveness at the group level may conflict with the physicians' desire to prescribe the best available treatment to their patients irrespective of economic consequences.
At the same time, societies increasingly expect that physicians actively involve patients in the management of their disease. Preference-based medicine is expected to increase patient trust, satisfaction with care and adherence to treatment plans, and thus improve health outcomes. Recent studies revealed that informed patients use less health care and thus reduce health care costs [79] . For the EULAR, patient preference is one of three overarching principles for the management of RA, emphasizing its importance [10] . Although the term patientcentred care is omnipresent in RA care, implementation to clinical reality remains a challenge.
The addition of the economic and patient perspective has increased the complexity of treatment decisions substantially. It is not fully understood whether rheumatologists are prepared to manage this new level of complexity. In the majority of developed countries, rheumatologists remain largely autonomous in reaching individual treatment decisions for their RA patients. In this role as key players in their health care systems, rheumatologists still have influence on the efficient use of health care resources.
To continually improve high quality healthcare [11] , insight is needed into how rheumatologists value the changing dimensions of RA treatment. There is limited knowledge about how rheumatologists make treatment choices and whether they are willing to trade off benefits and costs in clinical practice. In addition, the extent to which rheumatologists are willing to consider patients' preferences in daily clinical practice and comply, despite potential challenges, with existing theoretical frameworks is still unknown.
The aim of the study was therefore to investigate to what extent rheumatologists consider costs, cost-effectiveness and patients' preferences in addition to safety and efficacy in RA treatment decisions and to gain insights into contextual factors (e.g. age, gender or work environment) that potentially contribute to the relative importance of these treatment characteristics.
Methods
In this cross-sectional study, a discrete choice experiment (DCE) was designed to investigate relative preferences of rheumatologists when choosing drug treatments in RA. DCEs have been increasingly used to elicit preferences in health care [12] . In a DCE interventions are described by characteristics (attributes) and accompanying levels. Respondents are asked to repeatedly choose their preferred treatment in a series of choice sets between two alternative (hypothetical) treatment options that vary in the attributes of interest. The survey included Dutch clinical personnel (rheumatologists) only. Ethical approval was not required for this type of study.
Selection of attributes and levels
When developing a DCE, the selection of attributes and levels is fundamentally important to obtain valid results for a specific research question [13, 14] . In this study, a stepwise approach was followed that emphasized that patients' preferences and the economic dimension of treatment had to be included to meet the study objectives. First, potentially important attributes and levels were identified from the literature [2, 13, 1524] . Second, an initial list of attributes was agreed with an expert group (n = 6) consisting of rheumatologists and methodologists in the field of economic evaluations, DCE and decision making. Third, the proposed candidate attributes, attribute definitions and levels were further discussed with other clinical rheumatologists (n = 8).
Five attributes and attribute definitions-efficacy (status and improvement of disease activity based on DAS 28 ), safety (risk of a serious adverse event; AE), patient's preference (level of agreement with treatment choice); annual drug costs, and a cost-effectiveness ratio (compared with usual care)-and three levels per attribute were finally agreed and approved by the expert group. Details for all attributes and levels can be seen in Table 1 .
Experimental design
To limit the number of choice sets in the DCE [25] and thus increase response rate and/or improve response reliability [26] , a Bayesian efficient experimental design including 14 choice sets was computed (using Ngene software [27] ). A Bayesian design maximizes precision of estimated parameters for a given number of choice questions [28] , by incorporating a priori information about the sign and value of parameters. The a priori information needed to generate the choice sets was obtained from a pilot DCE experiment with 10 rheumatologists. Further, to avoid implausible treatment options, the experimental design was restricted to realistic combinations between efficacy, costs and cost-effectiveness. Finally, to ensure reliability, a dominance test (choice set with one treatment option clearly dominating the other to ensure that treatment options were carefully reviewed by respondents) and two retest choice sets (repetition of a choice set to assess testretest reliability) were integrated in the final design. A total of 17 choice sets, each presenting two unlabelled www.rheumatology.oxfordjournals.org treatment options (A and B), were included in the survey. An example of a choice set is shown in Table 3 .
Development of patient profiles
When making choices in the DCE, it is important that all respondents are considering the same patient. We selected a profile that addresses a clear need for change in the treatment regimen and a decisional problem in terms of balancing efficacy, safety, patient's preference and the economic consequences (absolute costs and cost-effectiveness ratio). The patient profile was developed by the expert group and reviewed by rheumatologists (n = 8) and resulted in a profile of a patient with anti-citrullinated positive RA and moderate disease activity despite two synthetic DMARDs (Table 2) .
Data collection and recruitment of rheumatologists
All certified Dutch rheumatologists that were registered in the Dutch Society of Rheumatology were invited by email to participate in the English online survey. In the questionnaire, a description of the DCE task was followed by an explanation of the attributes and levels. Further the patient profile was presented. After completion of the 17 choice tasks, respondents were asked to indicate on a 010 numeric rating scale how difficult they found the DCE task. Participants were further asked to indicate on a series of numeric rating scales their perceived importance of costs in clinical practice, perceived importance of cost-effectiveness considerations in reimbursement decisions, their level of agreement with present reimbursement criteria and their knowledge on cost-effectiveness. Finally, respondents were asked to provide socio-demographic data (e.g. age, gender, work environment and years of work experience). The full questionnaire can be found in Supplementary Appendix S1, available at Rheumatology Online. The survey was piloted among rheumatologists In the choice sets, also changes of the individual DAS28 components (tender joint count, swollen joint count, ESR, patient global assessment of disease activity) are presented in Tables 2 and 3 . b ICER is expressed in costs (euro) per QALY gained for the selected treatment compared with usual care. ICER: incremental cost effectiveness ratio; QALY: quality-adjusted life year. (n = 14) who did not contribute to previous development steps to ensure that choice sets, attributes and levels were relevant, clear and comprehensive.
Statistical analysis
Responses were considered for data analysis when at least 50% of choice sets were completed and participants successfully passed the dominance test. The DCE provides the respondent's preferred treatment choice among two presented alternatives. A panel random parameters logit (RPL) model was used to analyse data using Nlogit, version 5 [29] . This analysis provided the observable relative preference (utility U) of rheumatologist (i) for a treatment choice (j), which can be defined as a sum of preference scores for attributes/levels.
b 0 is the constant, b 18 are the mean attribute utility weights (physicians' preferences) for the respective attribute and Z i represents the S.D. of the random parameter for rheumatologist i. Dummy coding was used (for ease of interpretation of the results) to describe variables b 16 . Reference categories for efficacy, safety and patient's preference were moderate response, very rare and neutral patient attitude, respectively. The signs of the b coefficients indicate whether the attribute has a negative or positive effect on the rheumatologists' preference. The coefficients b 16 represent the change in preference compared with the reference category, the coefficient for costeffectiveness (b 7 ) describes the change of preference per increments of E10 000/quality-adjusted life year (QALY) and the coefficient for overall medication costs (b 7 ) the change in preference for each E1000 increase in annual treatment costs. An RPL model allows model parameters to vary between respondent, which is reflected in the random parameter (called S.D., b S.D. , Z S.D. ). If this random parameter is significantly different from zero, this is interpreted as evidence of significant preference variation for the attribute within the population [30] . In our study, all parameters were included as random parameters and assumed to be normally distributed. Overall model fit was estimated using McFadden's pseudo R 2 . To assess whether the attitude of rheumatologists towards patients' preferences was independent of the attitude towards safety and efficacy, interactions between patients' preference and efficacy as well as patients' preference and side effects were tested.
To estimate the relative importance of the attributes, relative importance weights were calculated using the method described by Malhotra and Birks [31] . The relative importance weights were derived by dividing the range of the level coefficients for one attribute by the sum of ranges of all attributes.
This method assumes that the relative importance of an attribute is based on the range of attribute levels. Changing attribute levels could have led to different conclusions. Attribute levels were, however, based on a plausible range of options. Flynn et al. [32] suggest using comparable scales to assess relative attribute impacts, for example, calculating marginal rates of substitution instead. The marginal rates of substitution (MRS) represent the extra (or saved) annual drug costs that rheumatologists consider acceptable for additional (or foregone) benefits when compared with the reference level. MRS was estimated for the non-monetary attributes that contributed significantly to the rheumatologists' choice. Cost-effectiveness presented in costs (E) per QALY gained for the selected treatment compared with usual care. PGA: patient global assessment of disease activity; QALY: quality-adjusted life year; SJC: swollen joint count; TJC: tender joint count.
www.rheumatology.oxfordjournals.org Subgroup analyses were conducted to better understand patterns that contribute to the variation in observed preferences. Different subgroup analyses were performed according to age (1 = younger than or equal to the median age and 2 = older than the median age), gender, work environment (1 = academic and 2 = non-academic setting) and self-assessed knowledge on cost-effectiveness analyses (1 = lower than or equal to the median and 2 = higher than the median).
A likelihood ratio (LR) test was used to assess differences between the subgroups of interest. When the LR test showed significant differences between subgroups (P < 0.05), a heteroskedastic conditional logit model was used to estimate interaction between each attribute and subgroups. A heteroskedastic model also takes into account heterogeneity in error variances across subgroups. A significant interaction term means significant difference in the coefficient across subgroups.
Results

Respondents' characteristics
Overall 235 rheumatologists were invited to participate, and 63 responses were finally included in the analysis. Mean (S.D.) age of the participating rheumatologists was 48.9 (7.6) years, and 44.4% were females. Rheumatologists assessed their knowledge on costeffectiveness as on average 6.4 (2.0) and their level of agreement with reimbursement criteria was 8.0 (1.9) with 22.2% of respondents ranking the highest score (10) . Further details on the respondents' characteristics can be found in Table 4 .
Rheumatologists found the DCE task moderately difficult [mean (S.D.) 5.8 (1.9)]. In line with existing literature, 85.7% (retest 1) and 82.5% (retest 2) of respondents chose the same alternative in the testretest exercises [30] .
The panel RPL model
The main results of the RPL model are presented in Table 5 . Compared with a moderate DAS28 response, rheumatologists preferred on average a good response without remission (b = 2.40) and even more a good response with remission (b = 4.40); both P < 0.001. No significant differences were observed in the relative importance of safety when risk of a serious AE increased from 0.005% (i.e. 5:100 000) to 0.05% (i.e. 5:10 000) or 0.5% (5:1000). Compared with a neutral attitude of the patient towards a drug, the patient's favouring a treatment (b = 0.29) increased preference (P < 0.1), and the patient's dislike of a treatment significantly reduced the rheumatologist's preference (b = À1.45, P < 0.001). The negative signs of costs and cost-effectiveness indicate that rheumatologists prefer a treatment with low cost and low incremental cost-effectiveness ratio (ICER). As revealed by the significance of the S.D., variation among respondents was observed for several attributes (levels). For some attributes the magnitude of the S.D. exceeded the mean estimate. Therefore, while uncommon severe side effects on average did not contribute to preference, some rheumatologists considered infrequent but serious AE important whereas others did not. Rheumatologists considered the ICER to some extent; however, the large and significant S.D. indicates some rheumatologists did not take ICER into account when making their treatment decisions. Overall model fit (R 2 ) was 0.46. No interaction between patient's preference and efficacy or safety was found.
Relative importance weight of treatment attributes
The relative importance of treatment attributes is shown in Fig. 1 . Treatment efficacy contributed most (43.8%) to the overall treatment preference (Fig. 1) . Economic aspects also played an important role, with absolute costs for medication being more relevant than relative costeffectiveness considerations (23.7% vs 13.7% contribution). Also patients' preferences were relevant for the treatment decision (17.3%) while the overall contribution of safety was limited (1.4%).
Marginal rates of substitution
About E16 000 and E29 000 additional medication costs per patient per year were considered acceptable by rheumatologists to achieve good response with or without remission, respectively, compared with moderate response. Further, rheumatologists accepted up to E2000 additional costs per year to align the treatment according to patients' preferences but the treatment should be at least E9000/year less costly to accept a treatment that patients dislike. All MRS can be found in Supplementary Appendix S2, available at Rheumatology Online.
Subgroup analyses
An LR test revealed significant (P < 0.05) differences between all subgroups (age, gender, work environment and knowledge on cost-effectiveness). Relative importance weights of subgroups also revealed some differences. However, when applying heteroskedastic interaction models to adjust for heterogeneity in error variances across subgroups, results revealed no significant (P < 0.1) differences between subgroup and attributes. A summary of the results can be found in Supplementary Appendix S3, available at Rheumatology Online.
Discussion
While efficacy is the most important driver for RA treatment decisions, this study revealed that rheumatologists also consider patients' preferences and economic aspects when selecting drug treatments for their patients. Among economic aspects, absolute medication costs, and only to a lesser extent cost-effectiveness, contributed to treatment decisions. Furthermore, rheumatologists take patients' preferences into account especially when patients express a dislike of a proposed treatment.
In line with present recommendations, clinicians primarily target for remission [6] . The frequency of serious AEs played a limited role in the choice of a drug treatment in patients with persistently active disease and previous treatment failures. This needs to be interpreted with caution as it naturally does not diminish the overall importance of safety in drug treatment choices for rheumatologists. Findings indicate that, in patients with active disease and bad prognostic factors, infrequent but serious AEs are less important compared with other treatment attributes. While during the design of the study there was no doubt about the importance of safety as an attribute, it should be noted that also during the preparation of the DCE there were important discussions on how to define 'safety' in the experiment. The majority of rheumatologists indicated manageable and reversible AEs would be irrelevant when treatment decisions involved a change after treatment failures. However, differences in opinion existed about whether the type or the frequency of serious AEs would matter most, and finally the latter received more support to serve as the definition for 'safety'. In line with these discussions, results revealed that the additional role of serious AEs varied importantly among respondents, especially when the likelihood of occurrence was above 0.05% and beyond. It is likely that in clinical practice also more common but less severe AEs are considered when choosing a drug treatment. Possibly, personal experiences of the clinician with serious AEs or the patient's individual attitude towards a particular risk influences individual decision; however, clear conclusions cannot be made from the present survey.
The study findings further revealed that rheumatologists trade off economic aspects of a treatment. Apparently, rheumatologists are concerned about optimal use of (limited) health care resources. Interestingly, medication costs were more important than relative cost-effectiveness. No significant difference was observed between clinicians who assessed their own knowledge of cost-effectiveness as high compared with clinicians who assessed their knowledge as moderate or low. This was surprising as an ICER provides more rational information on how to optimally spend resources (i.e. where to gain most QALYs for the same amount of money); likely in clinical practice rheumatologists are driven by the short-term budget considerations in their direct work environment even if decisions are made at the expense of fewer QALYs gained at societal level. Although knowledge about cost-effectiveness did not affect treatment choices, rheumatologists may still find an ICER difficult to interpret, and most likely, difficult to incorporate into clinical practice. Cost-effectiveness data, for example, do not provide an indication of how much money is spent on an annual basis (a frequently used tool to manage health care budgets on hospital level) and do not explain how much it costs (annually) to treat one patient successfully.
The results on the importance of patients' preferences in treatment decisions indicate that rheumatologists are moving towards patient-centredness and shared decision making. Although often viewed as important, there can be various and legitimate reasons to not actively involve patients in the treatment decision process [33, 34] . Of interest, rheumatologists acknowledged patients' preferences, especially when patients expressed disagreement with treatment choices. Apparently healthcare providers recognize such negative feelings might result in lack of adherence and decisional conflicts within patients. Ongoing initiatives that develop tools that support patients to fully understand their disease, treatment options and the associated benefits and risks may help them to communicate with the physician [35] .
Subgroup analyses for age, gender, work environment and knowledge on cost-effectiveness suggest that there are no significant differences in attitudes between subgroups. Possibly, strong personal beliefs and experiences (independent of the tested group-characteristics) play an important role in treatment decisions.
The study has four limitations. First, the response rate was comparatively low and we cannot exclude selection bias. Participants represented the entire spectrum of age, work environment and experience, which suggests that the samples are representative. Second, although the Netherlands health care setting is comparable to other countries, especially other wealthy Western European countries, in many aspects (e.g. reimbursement criteria or local clinical guidelines for treatments) it is possible that attitudes towards economic considerations and patients' preferences differ across countries. Third, in the present study, a number of assumptions had to be made that may not be fully transferrable to clinical realities. Rheumatologists were forced to make a choice between two hypothetical treatments that varied in a limited number of independent attributes and levels that were narrowed in clear definitions. In reality, however, the decision about drug treatment may be a complex interplay of multiple factors, partly even dependent on each other (e.g. a patient's concern about AEs may result in a change of the physician's attitude towards the attribute's safety or the patient's preferences can be influenced by multiple aspects, e.g. affordability, convenience and safety). Also the study was specifically designed to evaluate the importance of economic evidence and patient preferences, and attributes describing these dimensions had to be included. However, during development of the survey, rheumatologists clearly confirmed the presented attributes as most relevant for treatment decisions in clinical practice. Finally this study provides only insight into stated preferences. Real practice observations (or revealed preferences) would be additionally informative; however, the design and execution of such a study would be difficult. According to earlier studies, support for shared decision making did not consistently reflect practical use. Specifically, although physicians tended to report a preference for a shared decision making (as also found in the present study), decisions were typically made more frequently by the physician alone [9] . This is the first study to investigate relative preferences in drug treatment choices among rheumatologists. Results of this experiment are descriptive, and cannot be considered normative. In an era where management of patients with chronic disease becomes increasingly complex, the data of the current study are relevant to starting a discussion and initiating further research on physicians' behaviour and how to make trade-offs in clinical practice between classic drug characteristics (mainly efficacy and safety) and economic aspects and/or patient preferences.
Conclusion
This study suggests that there is overall acceptance among rheumatologists of trading off efficacy and safety against economic aspects and patients' preferences when selecting a drug treatment for RA patients. However, variability is observed in the extent to which rheumatologists state they are accounting for these aspects of drug management. As the emphasis on healthcare expenditures and patient empowerment in clinical care is likely to increase, more research and better guidance on how to include these dimensions in increasingly complex clinical decisions is needed. 
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